Pharma News

On November 9, 2023, a historically significant day, fruquintinib was officially approved by the U.S. Food and Drug Administration (FDA), making it successfully available in the U.S. market.

This groundbreaking new indication approval is undoubtedly based on the excellent data from Merck's large-scale global Phase III clinical trial KEYNOTE-811.

On June 24, 2024, FORSUNPHARMA announced a major strategic move in its official announcement, planning to privatize its core innovative assets - Henlius - through an absorption and merger.

Semaglutide, the active ingredient in Novo Nordisk's Wegovy®, is a GLP-1 receptor agonist that works by binding to and activating the GLP-1 receptor, thereby exerting its effects in the treatment of obesity.

In the current healthcare landscape, the prevalence of pharmaceutical company advertising has become a focus of public concern.

In the current extreme climate environment, the hot and humid weather not only brings many inconveniences to people's daily lives, but also poses potential health risks to those who are taking medications.

In recent years, with growing public interest in health and weight management, the market acceptance of new weight loss drugs such as Ozempic, Wegovy, and Mounjaro has been steadily increasing.

In recent years, the treatment of primary biliary cholangitis (PBC) has seen remarkable progress, with the continuous introduction of new drugs bringing good news to PBC patients worldwide.

Recently, the U.S. Food and Drug Administration (FDA) published an important update on its official website, announcing the implementation of automatic detention on herbal medicine and Yuquan pill products exported by a Chinese company.

In the tumultuous world of the pharmaceutical industry, the Swiss pharmaceutical giant Roche has once again demonstrated its firm steps in acquisitions and expansions.

Jichuan Pharmaceutical, a pharmaceutical company that has been deeply engaged in the field of children's medicines for many years, has recently announced its impressive first-quarter financial results for 2024.

In recent years, as people's living standards have improved and dietary structures have changed, the problems of overweight and obesity have become increasingly prominent, becoming an important public health issue globally.

MustangBio, a leading U.S. biotech company, has recently achieved a remarkable breakthrough.

Respiratory diseases, as a major challenge in the field of global public health, have always been the focus of the global medical community and the public.

Gilead Sciences, a leading global biopharmaceutical company, has actively pursued a series of large-scale merger and acquisition (M&A) strategies over the past five years.

Large pharmaceutical companies often rely on aggressive acquisition strategies to drive innovation and growth.

Huntington's disease, a rare hereditary neurodegenerative disorder, has been through more than 150 years of exploration.

Recently, Ming Jie Bio officially announced that it has formally licensed the global rights of the TL1A antibody FG-M701 to AbbVie.

When it comes to Lianrui Pharmaceutical, the public may not be too familiar with the company.

As China's population is rapidly aging, Alzheimer's disease (AD) has gradually emerged as a major public health challenge facing the country.